• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基线营养状况是食管癌根治性放化疗后的预后因素。

Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.

作者信息

Clavier J-B, Antoni D, Atlani D, Ben Abdelghani M, Schumacher C, Dufour P, Kurtz J-E, Noel G

机构信息

Department of Radiation Oncology, Paul Strauss Cancer Center, Strasbourg, France.

出版信息

Dis Esophagus. 2014 Aug;27(6):560-7. doi: 10.1111/j.1442-2050.2012.01441.x. Epub 2012 Oct 26.

DOI:10.1111/j.1442-2050.2012.01441.x
PMID:23106980
Abstract

Identify prognostic factors for survival and patterns of treatment failure after definitive radiochemotherapy for esophageal cancer. Between 2003 and 2006, 143 patients with squamous cell carcinoma and adenocarcinoma of the esophagus were retrospectively reviewed. Median age was 65 years (42-81). Median radiation dose was 62.5 Gy (38-72) with 1.8-2 Gy fraction. Median follow-up was 20.8 months (2.8-92.4). Three and 5-year local recurrence-free survival rates were 58.3% and 50.9%. In univariate analysis, traversable esophageal stricture was a prognostic factor. Three, 5-year locoregional recurrence-free survival rates were 42.4% and 34.9%. In multivariate analysis, traversable esophageal stricture and stage < IIB were independent prognostic factors. Three and 5-year disease-free survival rates were 30.5% and 25.9%. In multivariate analysis, Nutritional Risk Index (NRI) ≥ 97.5 and performance status (PS) = 0 were independent prognostic factors. Median, 3, and 5-year overall survival rates were 22.1 months, 34.4%, and 19.8%. In multivariate analysis, independent prognostic factors were NRI ≥ 97.5 and PS = 0. Median survival times for the NRI classes (no denutrition, moderate and severe denutrition) were 29.5, 19.7, and 12 months (P = 0.0004), respectively. A major impact of baseline NRI was found in terms of survival; it should be included in future prospective trials.

摘要

确定食管癌根治性放化疗后的生存预后因素及治疗失败模式。回顾性分析了2003年至2006年间143例食管鳞状细胞癌和腺癌患者。中位年龄为65岁(42 - 81岁)。中位放疗剂量为62.5 Gy(38 - 72 Gy),每次分割剂量为1.8 - 2 Gy。中位随访时间为20.8个月(2.8 - 92.4个月)。3年和5年局部无复发生存率分别为58.3%和50.9%。单因素分析中,可通过的食管狭窄是一个预后因素。3年和5年区域无复发生存率分别为42.4%和34.9%。多因素分析中,可通过的食管狭窄和分期<IIB是独立的预后因素。3年和5年无病生存率分别为30.5%和25.9%。多因素分析中,营养风险指数(NRI)≥97.5和体能状态(PS)=0是独立的预后因素。中位、3年和5年总生存率分别为22.1个月、34.4%和19.8%。多因素分析中,独立的预后因素为NRI≥97.5和PS =0。NRI分级(无营养不良、中度和重度营养不良)的中位生存时间分别为29.5个月、19.7个月和12个月(P =0.0004)。发现基线NRI对生存有重大影响;未来的前瞻性试验应纳入该指标。

相似文献

1
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.基线营养状况是食管癌根治性放化疗后的预后因素。
Dis Esophagus. 2014 Aug;27(6):560-7. doi: 10.1111/j.1442-2050.2012.01441.x. Epub 2012 Oct 26.
2
[Esophageal cancer: outcome according to therapeutic strategy].[食管癌:根据治疗策略的结果]
Cancer Radiother. 2013 Feb;17(1):10-20. doi: 10.1016/j.canrad.2012.10.011. Epub 2012 Dec 25.
3
Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.中晚期不可切除食管癌根治性放化疗的预后因素。
Dis Esophagus. 2012 Aug;25(6):545-54. doi: 10.1111/j.1442-2050.2011.01286.x. Epub 2011 Dec 2.
4
Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.单机构对食管癌腺癌术前与根治性放化疗的回顾性比较
Ann Surg Oncol. 2014 Nov;21(12):3744-50. doi: 10.1245/s10434-014-3795-2. Epub 2014 May 23.
5
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.在荷兰东北部进行的基于人群的研究:明确(放)化疗后食管癌患者的生存情况。
Ann Surg Oncol. 2013 Jun;20(6):1985-92. doi: 10.1245/s10434-012-2824-2. Epub 2012 Dec 29.
6
[The multimodality therapy of advanced inoperable esophageal carcinoma. A retrospective analysis].[晚期不可手术食管癌的多模态治疗。一项回顾性分析]
Strahlenther Onkol. 2000 Aug;176(8):350-5.
7
High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.高剂量根治性同步放化疗治疗非转移性局部晚期食管癌:毒性和结果。
Dis Esophagus. 2010 Apr;23(3):244-52. doi: 10.1111/j.1442-2050.2009.00999.x. Epub 2009 Jul 31.
8
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.回顾性分析术前同期放化疗加或不加选择性淋巴结照射治疗食管鳞癌的疗效差异。
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e593-9. doi: 10.1016/j.ijrobp.2011.04.032. Epub 2011 Jun 12.
9
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.术前放化疗后病理完全缓解的食管癌患者的预后。
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.
10
Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.每日低剂量持续输注5-氟尿嘧啶和顺铂同步放化疗(LDFP)治疗I-II期食管癌的长期疗效
Dis Esophagus. 2018 Apr 1;31(4). doi: 10.1093/dote/dox138.

引用本文的文献

1
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis.癌症免疫治疗中的营养状况与无进展生存期和总生存期:MOUSEION - 010荟萃分析
Immunotherapy. 2025 Mar;17(4):269-281. doi: 10.1080/1750743X.2025.2483656. Epub 2025 Mar 25.
2
The Effect of Rabdosia rubescens on Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients: A Phase II Clinical Study.冬凌草对鼻咽癌患者放疗所致口腔黏膜炎的影响:一项II期临床研究。
Integr Cancer Ther. 2025 Jan-Dec;24:15347354251314499. doi: 10.1177/15347354251314499.
3
A novel integrated nutrition-combined prognostic index for predicting overall survival after radical gastrectomy.
一种用于预测根治性胃切除术后总生存期的新型综合营养联合预后指数。
Front Nutr. 2024 Nov 18;11:1438319. doi: 10.3389/fnut.2024.1438319. eCollection 2024.
4
The distribution of esophageal cancer patients enrolled in care at the Uganda Cancer Institute by sub-regions, districts and ethnicity.乌干达癌症研究所登记在册的食管癌患者在各分区、各县和各民族间的分布情况。
Afr Health Sci. 2024 Mar;24(1):198-205. doi: 10.4314/ahs.v24i1.24.
5
Correlation between changes in nutritional status and tumor response in patients receiving immunotherapy for lung cancer (NUTIMMUNO study).肺癌患者接受免疫治疗时营养状况变化与肿瘤应答的相关性(NUTIMMUNO 研究)。
Support Care Cancer. 2024 Apr 27;32(5):312. doi: 10.1007/s00520-024-08519-x.
6
May Nutritional Status Positively Affect Disease Progression and Prognosis in Patients with Esophageal and Pharyngeal Cancers? A Scoping Review of the Current Clinical Studies.营养状况是否能积极影响食管和咽喉癌患者的疾病进展和预后?当前临床研究的范围综述。
Med Sci (Basel). 2023 Oct 2;11(4):64. doi: 10.3390/medsci11040064.
7
Efficacy and cost-effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059).无法切除的局部晚期食管癌患者同步放化疗中经皮内镜胃造口术(GASTO 1059)的疗效和成本效益分析。
Cancer Med. 2023 Jul;12(14):15000-15010. doi: 10.1002/cam4.6136. Epub 2023 Jun 16.
8
Geriatric Radiation Oncology: What We Know and What Can We Do Better?老年肿瘤放射治疗学:我们了解多少,我们能做得更好?
Clin Interv Aging. 2023 May 4;18:689-711. doi: 10.2147/CIA.S365495. eCollection 2023.
9
The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer.营养状况对晚期食管癌纳武利尤单抗治疗患者的影响。
PLoS One. 2023 May 5;18(5):e0285365. doi: 10.1371/journal.pone.0285365. eCollection 2023.
10
Routine Preoperative Nutritional Optimization Not Required in Patients Undergoing Breast Reconstruction.接受乳房重建手术的患者无需进行常规术前营养优化。
Breast Care (Basel). 2022 Oct;17(5):495-500. doi: 10.1159/000524638. Epub 2022 Apr 21.